First Tracks Biotherapeutics' stock price hit a nearly three-week high. Shares recently rose 21.7% after the company reported positive results for celiac disease drug tests.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.